TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Clinical diagnosis of CDAD plus laboratory diagnostic test~* No more than 24 hrs antimicrobial treatment for current CDAD episode~* No more than 3 episodes of CDAD in prior 12 months~* No previous episode of CDAD within 30 days of study enrollment~* Female subjects of childbearing potential must use adequate contraception~Exclusion Criteria:~* Life-threatening or fulminant colitis~* Concurrent use of antibiotics or any other treatments for CDAD~* History of inflammatory bowel disease (ulcerative colitis, Crohn's disease)~* Participation in other Clinical research studies within one month of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- SMT19969 (Type: EXPERIMENTAL): 200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
- Vancomycin (Type: ACTIVE_COMPARATOR): 125 mg capsule four times a day for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indocyanine Green for Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients over 18 years of age~2. Patients presenting with a solid tumor presumed to be resectable cancer and are at risk for local recurrence on pre-operative assessment~3. Good operative candidate as determined by the treating physician and multidisciplinary team~4. Subject capable of giving informed consent and participating in the process of consent.~Exclusion Criteria:~1. Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery~2. Subjects with a history of iodide allergies~3. Vulnerable patient populations~   1. People who would be easily lost to follow up~  2. Patients unable to participate in the consent process (children and neonates).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICG injection group (Type: EXPERIMENTAL): This group will receive a single dose of ICG, infused over 40 minutes. During surgery, they will be imaged with a camera and an imaging probe the investigators have developed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject completed the Treatment Period of the lead-in study, L-CP07-167 (NCT00635817), and has documented luteinizing hormone suppression as evidenced by peak-stimulated luteinizing hormone \<4 mIU/mL at the Month 6 study visit of the lead-in study.~* Demonstrated suppression of the physical signs of puberty at Month 6 of the lead-in study.~* Subject is expected to receive at least 12 months of therapy to treat Central Precocious Puberty after study entry.~* In general good health with no uncontrolled, clinically significant disease which would interfere with bone maturation or mask the objectives of this protocol as assessed by the investigator.~Exclusion Criteria:~* Incomplete precocious puberty, peripheral precocious puberty or evidence of any abnormal pituitary, hypothalamic, adrenal, thyroid and gonadal function (other than premature secretion of gonadotropins) not adequately controlled, unstable intracranial tumors except hamartoma.~* Bone age ≥14 years for girls and ≥15 years for boys (based on the Month 6 lead in study, L-CP07-167, radiographic results).~* Has an abnormal laboratory value suggesting a clinically significant underlying disease or condition.~* Chronic illness requiring treatment that may interfere with growth, ie, chronic steroid use, renal failure, moderate to severe scoliosis.~* Current therapy with medroxyprogesterone acetate.~* Current therapy with growth hormone.~* Current therapy with insulin-like growth factor-1 (IGF-1).~* Current use of an estrogen preparation.~* Any concomitant medical condition that, in the opinion of the investigator, may expose a subject to an unacceptable level of safety risk or that affects subject compliance.~* Subject has a positive pregnancy test.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Leuprolide Acetate 3M Depot 11.25 mg (Type: EXPERIMENTAL): Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
- Leuprolide Acetate 3M Depot 30 mg (Type: EXPERIMENTAL): Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Smoking, Abstention and Nicotine Replacement Therapy on Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* daily smokers smoking between 15-25 cigarettes per day and never smokers~Exclusion Criteria:~* chronic medical disease~* atopic dermatitis or other skin disease~* pregnancy~* menopause~* allergy to dressings or patches~* current or recent medication with corticosteroids or NSAID

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- continuous smoking (Type: ACTIVE_COMPARATOR): subjects smoke 20 cigarettes per day
- smoking cessation and NRT (Type: ACTIVE_COMPARATOR): subjects quit smoking and use transdermal nicotine patch
- smoking cessation and placebo patch (Type: PLACEBO_COMPARATOR): subjects quit smoking and use placebo patch
- never smokers (Type: NO_INTERVENTION): subjects being never smokers and who refrain from smoking

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory patients aged \>/= 50 years~* Diagnostic evidence of probable Alzheimer's disease consistent with criteria from the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)~* Confirmatory magnetic resonance imaging (MRI) or computed tomographic (CT) scan within the prior 12 months.~* Mini-Mental State Examination (MMSE) scores \>/= 3 and \</= 14 at Screening (Visit 1) and Baseline (Visit 2)~* Ongoing daily acetylcholinesterase inhibitor (AChEI) therapy at a stable dose for at least 3 months prior to Screening (Visit 1). It is preferred that patients continue to receive the same AChEI therapy for the duration of the study.~Exclusion Criteria:~* Patients with a modified Hachinski Ischemia Score greater than 4 at Screening.~* Patients who have taken memantine within one month of Screening (Visit 1)~* Patients who have a known hypersensitivity to memantine, neramexane, rimantadine, or amantadine.~* Patients whose AChEI therapy is likely to be interrupted or discontinued during the course of the study.~* Patients who are receiving therapy with more than one AChEI.~* Patients with computed tomography (CT) or magnetic resonance imaging (MRI) evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection, or any clinically significant central nervous system disease other than Alzheimer's disease.~* Patients with a DSM-IV Axis I disorder other than Alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder.~* Patients who, in the clinician's judgement, are likely to be placed in a nursing home within the next 6 months.~* Patients who had evidence of other neurological disorders that included, but were not limited to, stroke, Parkinson's disease, seizure disorder, or head injury with loss of consciousness within the prior 5 years~* Patients who had dementia that was complicated by other organic disease~* Patients who had dementia complicated by the presence of predominant delusions

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration, once daily.
- Memantine ER (Type: ACTIVE_COMPARATOR): 28mg, once daily. Oral administration for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent including authorization to release health information~* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS) scale~* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity (PFWS) scale~* Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial~Exclusion Criteria:~* Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis~* Active skin disease, infections or inflammation at the injection sites~* Plan to receive botulinum toxin type A anywhere in the face through the duration of the study~* History of allergy or sensitivity to any botulinum toxin preparations or to any component of the test article~* Current enrollment in an investigational drug or device trial or participation in such a trial within the last 30 days prior to screening through end of trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DaxibotulinumtoxinA 40 units (Type: EXPERIMENTAL): Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methadone Maintenance for Prisoners

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Heroin dependence in the year prior to current incarceration~* 3-6 months left to serve in prison-male pre-release inmate suitability for methadone maintenance as determined by medical evaluation~* Willingness to enroll in methadone maintenance~* Having a Baltimore address~Exclusion Criteria:~* Pending parole hearing~* Pending charges~* Kidney failure~* Liver failure

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 3 (Type: EXPERIMENTAL): None
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-pregnant female aged ≥ 18 years who is in good general health~2. Diagnosis of BV~3. Willing to refrain from using any intravaginal product (e.g., spermicide, tampon, douche, feminine deodorant spray, diaphragm, vaginal ring birth control, or condom with spermicide or insertion into the vagina of any drug or non-drug product during treatment), other than study treatment for the duration of the trial~4. Subjects of childbearing potential who have a negative urine pregnancy test at the Entry Visit (Visit 1) and agree to use an acceptable form of birth control throughout the study~5. Able to understand and willing to sign the informed consent form (ICF) and able to comply with the requirements of the protocol~Exclusion Criteria:~1. History of alcohol or substance abuse~2. Experienced a clinically significant medical event within 90 days~3. Abnormal pap or high risk human papillomavirus (HPV)~4. History or presence of clinically significant central nervous system (CNS), cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, gynecologic, dermatologic, neurologic, oncologic, or psychiatric disease~5. Pregnant, lactating, or planning to become pregnant or breastfeed during the study period~6. Primary or secondary immunodeficiency~7. Evidence of any vulvovaginitis at screening other than BV~8. History of hypersensitivity or allergy to metronidazole, parabens, other nitroimidazole derivatives, or other ingredients of the GDC 229 (metronidazole 0.75% vaginal gel), metronidazole 0.75% vaginal gel (Oceanside Pharmaceuticals), or vehicle gel~9. Participating in another clinical trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Drug (Type: EXPERIMENTAL): GDC-229 gel applied vaginally as directed.
- Reference Drug (Type: ACTIVE_COMPARATOR): Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
- Vehicle Placebo Gel (Type: PLACEBO_COMPARATOR): GDC-229 Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female volunteers 18 years of age or older~Exclusion Criteria:~* any auto-immune disease or other serious acute, chronic or progressive disease~* hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine.~* history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine.~* within the past 7 days, they have experienced: any acute disease, infections requiring systemic antibiotic or antiviral therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL~* HCV genotype 2~* Chronic HCV infection (≥ 6 months)~* Females of childbearing potential must have a negative serum pregnancy test~* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~* Must be of generally good health, with the exception of chronic HCV infection, as determined by the investigator.~Exclusion Criteria:~* Current or prior history of clinically-significant illness (other than HCV that may interfere with treatment, assessment or compliance with the protocol;~* Screening electrocardiogram (ECG) with clinically significant abnormalities~* Laboratory results outside of acceptable ranges at Screening~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks
- SOF+RBV (Type: EXPERIMENTAL): SOF+RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin in Minimal Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* Cirrhosis diagnosed on clinical grounds~* MHE diagnosed by abnormalities in a psychometric battery (NCT-A, NCT-B, ICT BDT and DST impaired beyond 2 standard deviations of known control values on any of the above 3 tests will be considered to have MHE)~* Current drivers (valid driving license and driving at least 20 miles/week)~* All women of child-bearing potential will be required to use effective contraception~Exclusion Criteria:~* Current or recent (\< 6 month) use of alcohol (AUDIT questionnaire will be used; any cirrhotic with a value of \> 0 will be excluded) and a positive blood alcohol level~* Use of antibiotics within last 6 weeks~* Allergy to rifaximin, rifabutin, rifampin, or rifapentine~* Infection or gastrointestinal hemorrhage within the last 6 weeks~* Renal insufficiency~* Hepatocellular carcinoma~* Psychoactive drug use, including interferon concurrently~* Non-drivers and those who drive less than 20 miles/week~* Pregnancy and breastfeeding~* Excluding patients with OHE:~  * Detailed neurological examination to check for dysarthria, asterixis, ataxia and disorientation~ * Detailed history-taking from friends/relatives only after taking the patient's permission~ * Mini-mental status examination \> 25~ * Episode of overt (clinical hepatic encephalopathy) within 6 months~ * Current treatment with lactulose, rifaximin, zinc, or metronidazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Will be given placebo and follow the exact procedures as the experimental section
- Drug (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Other criteria also apply

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG 162 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals who consent to participate in the study~* Residents in the study area~* Older than 6 months of age (or weighing more than 5Kg)~* Women in the second or third trimester who are not on IPTp~Exclusion Criteria:~* Individuals who do not consent to participate in the study~* Younger than 6 months of age (or weighing more than 5Kg)~* Women in the first trimester of pregnancy~* Severely ill individuals~* Individuals on contra-indicated medication

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Participants (Type: OTHER): Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete